Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
Condition: NonSmall Cell Lung Cancer Intervention: Drug: DZD9008 Sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | HER2 | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Research